Q-omics provides the consensus-scored FAM167A profile across patient tissues and cancer cell-line models. FAM167A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM167A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM167A RNA expression shows 17,058 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where FAM167A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM167A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM167A survival associations across molecular data types. FAM167A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM167A RNA expression–survival associations across cancer types. High FAM167A expression shows unfavorable associations in ACC, KIRC and UCEC, but favorable associations in HNSC, COAD and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM167A RNA expression.
This table summarizes FAM167A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM167A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM167A shows lower tumor expression in KIRC, THCA, KIRP, LUSC, LUAD and KICH. The KIRC box plot shows higher FAM167A RNA expression in normal versus tumor tissue (log2 FC = −3.225, t-test p < 0.001).
This table shows molecular features associated with FAM167A in patient tissues and cancer cell lines. In patient samples, FAM167A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM167A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
